Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TriCAR-T-CD19 Adoptive Immunotherapy for CD19-positive Refractory/Relapsed Non-Hodgkin Lymphoma

NCT03497533 is registered in ClinicalTrials.gov with Timmune Biotech Inc. as lead sponsor.

NCT NCT03497533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03497533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TriCAR-T-CD19 Adoptive Immunotherapy for CD19-positive Refractory/Relapsed Non-Hodgkin Lymphoma
Lead sponsor
Timmune Biotech Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 3, 2018
Completion date
December 31, 2020
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma,b cell